Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025
상품코드:1795399
리서치사:Current Partnering
발행일:2025년 08월
페이지 정보:영문 1500+ Pages
라이선스 & 가격 (부가세 별도)
한글목차
본 보고서에서는 제약 및 바이오테크놀러지 업계에 대한 조사 분석을 하고 기업이 전임상 단계 제휴 계약을 체결하는 방법과 이유, 이러한 제휴를 형성하는 주요한 재무적 및 전략적 조건에 관한 종합적인 데이터 주도의 분석을 제공합니다.
목차
주요 요약
제1장 서론
제2장 기업이 전임상 단계 화합물을 제휴하는 이유
소개
전임상 단계에서 파트너십의 역할
전임상 단계에서 라이선스 도입
전임상 단계에서 라이선스 공여
탐색 단계, 전임상 단계, 임상 단계 계약의 차이
전임상 단계 제휴 계약을 체결하는 이유
라이센서가 전임상 단계 계약에 참가하는 이유
라이센시가 전임상 단계 계약에 참가하는 이유
전임상 단계 제휴 계약의 장래
제3장 전임상 단계 계약 전략과 구조
소개
기업은 어느 단계에서 제휴할 것인가
제약 및 바이오테크놀러지에서 조기 제휴
제약 및 바이오테크놀러지의 만기 제휴
초기 단계와 후기 단계 제휴 - 위험과 비용 비교
기업은 전임상 단계 제휴에 얼마 지출하고 있는지
순수/다성분의 제휴 계약
순수한 라이선싱 계약의 구조
순수 전임상 단계 라이선싱 계약의 예
a. 사례 연구 9
b. 사례 연구 10
다성분 전임상 단계 제휴 계약
다성분 전임상 단계 조항의 예
a. 사례 연구 11
b. 사례 연구 12
제4장 전임상 단계 제휴의 결제 전략
소개
전임상 단계 결제 전략
결제 방법
헤드라인 금액
선불
대출
전환 대출
보통주
연구개발자금
라이선싱료
마일스톤 지불
로열티
퀴드
옵션 결제
제5장 전임상 단계 계약 동향
소개
연간 전임상 단계 제휴
전임상계약의 속성
전임상 단계 제휴 : 계약 유형별
전임상 단계 제휴 : 질환 유형별
전임상 단계 제휴 : 기술 유형별
가장 활발한 기업에 의한 전임상 단계 제휴(2020년-)
제6장 전임상 단계 제휴의 결제 조건
소개
전임상 단계 결제 조건에 관한 가이드라인
선불
마일스톤 지불
로열티 지불
전임상 단계 결제 조건 - 계약 데이터 분석
공개 데이터
조사 데이터
결제 조건 분석
전임상 단계 헤드라인 금액
전임상 단계 계약의 선불
전임상 단계 계약의 마일스톤 지불
전임상 단계 로열티 지불
제7장 전 주요 임상 단계 계약
소개
전임상 단계 상위계약(금액)
제8장 가장 활발한 전임상 단계 계약기업 상위 25개사
소개
가장 활발한 전임상 단계 계약 기업 상위 25개사
제9장 전임상 단계 제휴 계약 디렉토리
소개
전임상 단계 계약(2020년-)
제10장 전임상 단계 계약 : 개발단계별
소개
계약 : 전임상 단계별
부록
JHS
영문 목차
영문목차
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025)
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025 report provides a comprehensive, data-driven analysis of how and why companies enter preclinical-stage partnering agreements, as well as the key financial and strategic terms shaping these partnerships. This essential industry resource delivers unparalleled insights into the structure, negotiation dynamics, and financial considerations that define early-stage pharmaceutical and biotech collaborations.
At the preclinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's drug candidate or technology. These agreements are often multifaceted, beginning with collaborative R&D efforts and potentially culminating in commercialization agreements.
This report provides detailed intelligence on the latest preclinical-stage agreements in the healthcare sector, helping companies evaluate market trends, optimize negotiation strategies, and benchmark deal structures.
A Must-Have Resource for Biotech and Pharma Dealmakers
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.
With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:
Benchmarking deal structures and financial terms
Optimizing negotiation strategies
Assessing potential partners' flexibility
Identifying trends in preclinical-stage partnerships
Why This Report is Essential for Dealmakers
Understanding a potential partner's negotiation flexibility and deal structures is critical when entering preclinical-stage partnerships. While headline financial figures (e.g., upfront payments, milestones, royalties) are important, contract documents reveal the precise triggers and conditions for these payments-details that are often missing from press releases and traditional deal databases.
This report provides a comprehensive listing of over 1,670 preclinical-stage deals announced since 2020, including financial terms where available. Additionally, it includes direct links to online deal records, along with publicly available contract documents submitted to the SEC.
By analyzing these agreements, companies can gain critical insights to refine deal strategies, assess partner flexibility, and structure competitive agreements.
Comprehensive Analysis of Preclinical-Stage Partnering Trends
The first chapters of this report offer a detailed orientation to preclinical-stage deal-making, including:
Chapter 1 - Introduction to the report
Chapter 2 - Why companies engage in preclinical-stage partnerships
Chapter 3 - Strategic approaches and deal structures, with case studies
Chapter 4 - Payment strategies, including upfronts, milestones, and royalties
Chapter 5 - Analysis of preclinical-stage deal activity (2020-2025), categorized by year, stage of development, therapeutic area, technology type, and key dealmakers
Chapter 6 - In-depth financial analysis of headline values, upfront payments, milestone triggers, and royalty rates
Chapter 7 - A review of the leading preclinical-stage deals by headline value
Chapter 8 - Profiles of the top 25 most active preclinical-stage dealmakers
Chapter 9 - A database of preclinical-stage partnering agreements, including contract documents where available
Chapter 10 - A comprehensive directory of all preclinical-stage deals announced since 2020
Key Benefits of the Report
This must-have industry resource provides exclusive insights to help companies assess, structure, and negotiate their own preclinical-stage partnerships. Key benefits include:
Time-Saving Market Intelligence - Eliminate the need for manual research with ready-to-use insights on industry trends and deal structures.
Unmatched Financial Data Access - Gain exclusive insight into headline values, upfront payments, milestone structures, and royalty terms to optimize negotiations.
Comprehensive Deal Database - Access over 1,670 preclinical-stage agreements, including contract documents where available.
Deep-Dive into Industry Leaders - Analyze actual preclinical-stage deals entered into by the top 25 global pharma and biotech companies, alongside emerging players.
Strategic Case Studies & Deal Analysis - Examine real-world deal structures and negotiation strategies to enhance your own business development approach.
High-Value Deal Identification - Pinpoint the most lucrative preclinical-stage deals signed since 2020, gaining insight into premium industry transactions.
Profile the Most Active Dealmakers - Identify key players driving preclinical-stage collaborations, ensuring you engage with the right partners.
Full Deal Listings & Categorization - Navigate a complete A-Z listing of preclinical-stage agreements, categorized by company, development phase, deal type, therapeutic area, and technology focus.
Negotiate with Confidence - Understand the key terms and conditions agreed upon in previous deals, helping you structure optimal agreements.
Robust Due Diligence Support - Conduct data-backed assessments to determine the viability and competitiveness of your proposed deal terms.
Scope of the Report
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report provides:
Trends in preclinical-stage dealmaking in the biopharma industry since 2020
Detailed deal structures, including upfront, milestone, and royalty terms
Case studies of real-life preclinical-stage agreements
Access to over 1,670 preclinical-stage deals, with contract records where available
Profiles of the most active preclinical-stage dealmakers since 2020
Analysis of the highest-value preclinical-stage deals
Each deal record is indexed by:
Company (A-Z)
Headline Value
Deal Type
Specific Therapy Focus
Technology Focus
Critical Questions Answered
By analyzing actual contract agreements where available, this report provides definitive answers to critical questions such as:
What specific rights are granted in each agreement?
What exclusivity terms apply?
How is the deal structured financially? (Upfronts, milestones, royalties)
Who controls development, manufacturing, and commercialization?
How are intellectual property rights handled?
What are the termination conditions for the agreement?
What dispute resolution mechanisms are in place?
How are confidentiality and publication rights managed?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Why do companies partner preclinical stage compounds?
2.1. Introduction
2.2. The role of preclinical stage partnering
2.2.1. In-licensing at preclinical stage
2.2.2. Out-licensing at preclinical stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into preclinical stage partnering deals
2.4.1. Licensors reasons for entering preclinical stage deals
2.4.2. Licensees reasons for entering preclinical stage deals
2.5. The future of preclinical stage partnering deals
Chapter 3 - Preclinical stage deal strategies and structure
3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical / biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study 1
3.2.1.1.b. Case study 2
3.2.1.1.c. Case study 3
3.2.1.1.d. Case study 4
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study 5
3.2.2.1.b. Case study 6
3.2.2.1.c. Case study 7
3.2.2.1.d. Case study 8
3.3. Early and later stage partnering - a risk/cost comparison
3.4. What do companies spend on preclinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure preclinical stage licensing agreements
